Biosign Appoints Three New Members to Board of Directors

TORONTO, May 27, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO, "Biosign") announced today the appointment to its board of directors of Dr. Harold S. Koplewicz, Jason D. Meretsky, and Former Senator Alfonse D'Amato.

"We are pleased to welcome back Senator D'Amato and be joined by our new members, Dr. Koplewicz and Mr. Meretsky", said David Silver, the company's Chairman. "As Biosign embarks on an exciting period of change and growth, attracting a diverse range of leadership for our Board and management team is critical to our success".

Harold S. Koplewicz, M.D. is the Chairman of the Board of Directors of Delcath Systems Inc. (NASDAQ: DCTH). In 2009, he founded and became the President of the Child Mind Institute, the only independent non-profit organization in the USA, dedicated to transforming mental health care for the world's children. In 2007, Dr. Koplewicz became the first Vice Dean of External Affairs at the NYU Langone Medical Center. He has served as a member of the National Board of Medical Examiners and as a Commissioner of the New York State Commission on Youth, Crime and Violence and Reform of the Juvenile Justice System. He has also served as a member of the working group organized by the U.S. Assistant Surgeon General and the U.S. Department of Health and Human Services to address the effects of terrorism on children's mental health.

Jason D. Meretsky is a corporate securities lawyer with considerable business, transactional and legal experience, particularly in the technology sector. Mr. Meretsky previously served as Executive Vice President, Corporate Development of Avid Life Media Inc. and Vice President and General Counsel of Enghouse Systems Limited. (TSE: ESL). Mr. Meretsky serves on the board of directors and Audit Committee of Homeserve Technologies Inc. (previously listed on the TSX), the Board of Directors of CECO Environmental Inc. (Nasdaq: CECO), and a director and senior officer of LiveReel Media Corporation (OTCBB:LVRL). Mr. Meretsky previously practiced corporate and securities law as a partner with Goodman and Carr LLP. He is a member in good standing of the Canadian Bar Association and the Law Society of Upper Canada.

Former Senator Alfonse D'Amato had a distinguished 18-year career in the U.S. Senate, served as chairman of the Senate Banking Committee, was a member of the Senate Appropriations Committee and served on the Senate Finance Committee. Senator D'Amato is a current board member for Signature Bank (Nasdaq: SBNY), and he is Chairman of the Board for the Poker Players Alliance, an industry group that supports a repeal of the restrictive US internet gambling laws. From 1999 to 2009, he was a member of the board of CA Technologies (Nasdaq: CA), where he served on both the audit and the compensation committees, and he is a former director of Cendant Corporation.

In addition to these new appointments, Biosign announced the departure of two directors, Tony LaVista and Mouane Sengsavang, to focus on prior business commitments. "On behalf of the entire organization, we would like to express our sincere thanks to Tony and Mouane, both of whom made significant contributions to Biosign during their tenure on the Board", said Dr. Radu Leca, Biosign's Founder and CEO. "Special thanks are extended to Tony, who has served, since 2008, with great abnegation and competence, as Chair of Biosign's Audit Committee", added Leca.

The new Board, consisting of Radu Leca, David Silver, Harold Koplewicz, Jason Meretsky, and Alfonse D'Amato, is expected to further increase the company's capability to realize its commercial opportunities.

About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE Biosign Technologies Inc.

For further information:

Biosign Contact Information          
         
Colley Clarke
Biosign Technologies
Phone: (416) 218-9800 ext. 234
Email: cfo@biosign.com
        Alan S. Roemer
The Trout Group
Phone: (646) 378-2945
Email: aroemer@troutgroup.com

Organization Profile

Biosign Technologies Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890